Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identification and in vivo characterization of pharmacological chaperones of the dopamine transporter
EF 2010-11
Résumé
Schizophrenia is a mental illness affecting 0.7% of people in Canada, and is characterized by hallucinations, delusions as well as reduced emotional response and motivation. Due to the severity of the symptoms and chronic nature of this illness, schizophrenia costs billions of dollars annually in healthcare and loss of productivity. Drug treatments are available and have improved over the last ten years, but are only partially effective and have severe side-effects. Therefore, development of new drug treatments could lead to significant improvement of patient quality of life as well as the economic burden on society. The causes of schizophrenia are not clear, but likely involve the regulation of the neurotransmitter dopamine. Recently we discovered that genetically increasing a protein important in dopamine regulation, the dopamine transporter (DAT), can reduce schizophrenia-related behavioural deficits in a genetically altered mouse that serves to model certain aspects of schizophrenia. Although genetic regulation of DAT in humans is not currently practical, this observation suggests that regulation of the amount of DAT with drug treatment may be a treatment approach worth investigating, which is the subject of our research proposal.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
225375
Name
Beerepoot Pieter
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Identification and in vivo characterization of pharmacological chaperones of the dopamine transporter
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Models Of Mental Illness; Behavioural Assay; Dopamine; Dopamine Transporter; Elisa Cell Surface Expression Assay; Glutamate; Pharmacological Chaperone; Protein Folding; Schizophrenia; Transgenic Mice
Abstract
Schizophrenia is a mental illness affecting 0.7% of people in Canada, and is characterized by hallucinations, delusions as well as reduced emotional response and motivation. Due to the severity of the symptoms and chronic nature of this illness, schizophrenia costs billions of dollars annually in healthcare and loss of productivity. Drug treatments are available and have improved over the last ten years, but are only partially effective and have severe side-effects. Therefore, development of new drug treatments could lead to significant improvement of patient quality of life as well as the economic burden on society. The causes of schizophrenia are not clear, but likely involve the regulation of the neurotransmitter dopamine. Recently we discovered that genetically increasing a protein important in dopamine regulation, the dopamine transporter (DAT), can reduce schizophrenia-related behavioural deficits in a genetically altered mouse that serves to model certain aspects of schizophrenia. Although genetic regulation of DAT in humans is not currently practical, this observation suggests that regulation of the amount of DAT with drug treatment may be a treatment approach worth investigating, which is the subject of our research proposal.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beerepoot, Pieter
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~